HSBC/CALL/GILEAD SCIENCES/110/0.1/15.01.25 Stock

Warrant

DE000HG80R17

Market Closed - Börse Stuttgart 02:24:34 2024-07-05 am EDT
0.001 EUR 0.00% Intraday chart for HSBC/CALL/GILEAD SCIENCES/110/0.1/15.01.25
6 months-99.18%
Current year-98.72%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-05 0.001 0.00%
24-07-04 0.001 0.00%
24-07-03 0.001 -66.67%
24-07-02 0.003 -50.00%
24-07-01 0.006 +500.00%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 02:24 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying GILEAD SCIENCES, INC.
Issuer HSBC
WKN HG80R1
ISINDE000HG80R17
Date issued 2023-02-02
Strike 110 $
Maturity 2025-01-15 (192 Days)
Parity 10 : 1
Emission price 0.48
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.52
Lowest since issue 0.001
Spread 0.015
Spread %83.33%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Gilead Sciences, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.69 USD
Average target price
82.97 USD
Spread / Average Target
+24.41%
Consensus